<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="covidseq/PMC7138188/results/search/disease/results.xml">
  <result pre="has been investigated in patients with primary central nervous system" exact="lymphoma" post="(PCNSL) and non-Hodgkin lymphoma (NHL) with CNS involvement and"/>
  <result pre="patients with primary central nervous system lymphoma (PCNSL) and non-Hodgkin" exact="lymphoma" post="(NHL) with CNS involvement and has shown promising results."/>
  <result pre="(thiotepa, busulfan, cyclophosphamide) conditioning for PCNSL (27 patients), secondary CNS" exact="lymphoma" post="(SCNSL) (8 patients), or relapsed disease with CNS involvement"/>
  <result pre="CI, 58.6%-98.6%), respectively. The most common side effects were febrile" exact="neutropenia" post="(89.6%; of which 66.7% had an infectious etiology identified),"/>
  <result pre="of which 66.7% had an infectious etiology identified), nausea/vomiting (85.4%)," exact="diarrhea" post="(93.8%), mucositis (89.6%), and electrolyte abnormalities (89.6%). Four patients"/>
  <result pre="analyzed the data from 48 patients with central nervous system" exact="lymphoma" post="who had received high-dose chemotherapy and autologous stem cell"/>
  <result pre="primary or secondary central nervous system lymphoma. Keywords ASCT Non-Hodgkin" exact="lymphoma" post="PCNSL Relapse SCNL Introduction Both primary central nervous system"/>
  <result pre="PCNSL Relapse SCNL Introduction Both primary central nervous system (CNS)" exact="lymphoma" post="(PCNSL) and non-Hodgkin lymphoma (NHL) with CNS involvement have"/>
  <result pre="Both primary central nervous system (CNS) lymphoma (PCNSL) and non-Hodgkin" exact="lymphoma" post="(NHL) with CNS involvement have historically carried poor prognoses."/>
  <result pre="institution retrospective analysis of consecutive patients with PCNSL, secondary CNS" exact="lymphoma" post="(SCNSL), or relapsed CNS lymphoma who had undergone consolidative"/>
  <result pre="patients with PCNSL, secondary CNS lymphoma (SCNSL), or relapsed CNS" exact="lymphoma" post="who had undergone consolidative ASCT with TBC conditioning based"/>
  <result pre="groups of patients were included: those with PCNSL, defined as" exact="lymphoma" post="confined to the CNS, including intraocular lymphoma; those with"/>
  <result pre="the CNS, including intraocular lymphoma; those with SCNSL, defined as" exact="lymphoma" post="with systemic disease and CNS involvement; and those with"/>
  <result pre="and CNS relapse were grouped together as patients with systemic" exact="lymphoma" post="with CNS involvement, whether found at the initial diagnosis"/>
  <result pre="have infection. Bacterial infection was present in 58.3% and included" exact="pneumonia" post="(18.8%), colitis (16.7%; 10.4% with Clostridium difficile), bacteremia (10.4%;"/>
  <result pre="Bacterial infection was present in 58.3% and included pneumonia (18.8%)," exact="colitis" post="(16.7%; 10.4% with Clostridium difficile), bacteremia (10.4%; with organisms"/>
  <result pre="organisms that included Escherichia coli, Staphylococcus epidermidis, and coagulase-negative staphylococcus)," exact="urinary tract infection" post="(6.3%; with organisms that included coagulase-negative staphylococcus and E."/>
  <result pre="with organisms that included coagulase-negative staphylococcus and E. coli), and" exact="sinusitis" post="(2.1%). Viral infection was present in 45.8% of patients,"/>
  <result pre="infection was present in 45.8% of patients, including 33.3% with" exact="herpes simplex" post="virus mucositis, 2.1% with herpes simplex virus vaginitis, 2.1%"/>
  <result pre="patients, including 33.3% with herpes simplex virus mucositis, 2.1% with" exact="herpes simplex" post="virus vaginitis, 2.1% with coronavirus, 2.1% with rhinovirus, 2.1%"/>
  <result pre="parainfluenza, 2.1% with human herpesvirus 6 bacteremia, and 2.1% with" exact="viral pneumonia." post="Fungal infection was present in 8.3% of patients, including"/>
  <result pre="present in 8.3% of patients, including 6.3% with Candida glabrata" exact="urinary tract infection" post="and 2.1% with Candida dubliniensis bacteremia. Almost all patients"/>
  <result pre="bacteremia. Almost all patients developed nausea and vomiting (85.4%) and" exact="diarrhea" post="(93.8%). Mucositis was present in 89.6% of patients; 35.4%"/>
  <result pre="patients, with 4.2% developing seizure. Four patients (8.3%) developed hemorrhagic" exact="cystitis" post="as a result of cyclophosphamide. Renal injury occurred in"/>
  <result pre="Cardiac toxicity developed in 16.7% of patients, including 2.1% with" exact="cardiomyopathy" post="presumed secondary to cyclophosphamide and 14.6% with arrhythmia that"/>
  <result pre="cyclophosphamide and 14.6% with arrhythmia that included supraventricular tachycardia and" exact="atrial fibrillation" post="with a rapid ventricular response. Liver function abnormalities occurred"/>
  <result pre="Median 15.0 15.0 14.0 IQR 12.5-19.5 14.0-21.0 11.0-16.0 Toxicity Febrile" exact="neutropenia" post="43 (89.6) 25 (52.1) 18 (37.5) Infection 32 (66.7)"/>
  <result pre="3 (6.3) Seizure 2 (4.2) 1 (2.1) 1 (2.1) Hemorrhagic" exact="cystitis" post="4 (8.3) 2 (4.2) 2 (4.2) Renal injury 8"/>
  <result pre="result in poorer outcomes than those for patients with CNS" exact="lymphoma" post="in remission. 38 , 41 All the patients with"/>
  <result pre="instead contribute to increased toxicity. Four patients (8.3%) developed hemorrhagic" exact="cystitis" post="in our study. One study by Montemurro et al,"/>
  <result pre="= .008). • The most common side effects were febrile" exact="neutropenia" post="and infection, nausea/vomiting, diarrhea, mucositis, and electrolyte abnormalities, with"/>
  <result pre="Reni M. Gatta G. Ferreri A.J.M. Primary central nervous system" exact="lymphoma" post="Crit Rev Oncol Hematol 113 2017 97 110 28427529"/>
  <result pre="methotrexate with or without whole brain radiotherapy for primary CNS" exact="lymphoma" post="(G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial Lancet Oncol"/>
  <result pre="Randomized phase III study of whole-brain radiotherapy for primary CNS" exact="lymphoma" post="Neurology 84 2015 1242 1248 25716362 5 Abrey L.E."/>
  <result pre="autologous stem cell transplantation as first-line therapy for primary CNS" exact="lymphoma" post="in patients younger than 60 years: a multicenter phase"/>
  <result pre="stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary" exact="lymphoma" post="of the central nervous system Haematologica 93 2008 147"/>
  <result pre="rescue in 22 patients with refractory or recurrent primary CNS" exact="lymphoma" post="or intraocular lymphoma J Clin Oncol 19 2001 742"/>
  <result pre="patients with refractory or recurrent primary CNS lymphoma or intraocular" exact="lymphoma" post="J Clin Oncol 19 2001 742 749 11157026 10"/>
  <result pre="Damaj G. First-line autologous stem cell transplantation in primary CNS" exact="lymphoma" post="Eur J Haematol 75 2005 288 292 16146534 11"/>
  <result pre="Montemurro M. Kiefer T. Schuler F. Primary central nervous system" exact="lymphoma" post="treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation"/>
  <result pre="and ASCT without whole-brain radiotherapy for poor prognosis primary CNS" exact="lymphoma" post="Bone Marrow Transplant 31 2003 679 685 12692608 14"/>
  <result pre="TBC and autologous stem-cell transplant for newly diagnosed primary CNS" exact="lymphoma" post="Blood 125 2015 1403 1410 25568347 15 Chen Y.-B."/>
  <result pre="transplantation in patients with central nervous system involvement by non-Hodgkin" exact="lymphoma" post="Cancer 121 2015 226 233 25204639 16 Houillier C."/>
  <result pre="cell rescue (IC + HCR) for primary central nervous system" exact="lymphoma" post="(PCNSL) in young patients: an Intergroup Anocef-Goelams randomized phase"/>
  <result pre="stem cell transplantation for patients with primary central nervous system" exact="lymphoma" post="in first complete remission Cancer 123 2017 3073 28369839"/>
  <result pre="comprehensive assessment of toxicities in patients with central nervous system" exact="lymphoma" post="undergoing autologous stem cell transplantation using thiotepa, busulfan, and"/>
  <result pre="cell rescue in relapsed or refractory primary central nervous system" exact="lymphoma" post="and intraocular lymphoma: a retrospective study of 79 cases"/>
  <result pre="transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS" exact="lymphoma" post="J Clin Oncol 24 2006 3865 3870 16864853 22"/>
  <result pre="Atta J. Prognosis of patients with primary central nervous system" exact="lymphoma" post="after high-dose chemotherapy followed by autologous stem cell transplantation"/>
  <result pre="of autologous stem cell transplantation in primary central nervous system" exact="lymphoma" post="Blood 127 2016 1642 1649 26834241 26 Illerhaus G."/>
  <result pre="cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin" exact="lymphoma" post="Biol Blood Marrow Transplant 18 2012 76 83 21749848"/>
  <result pre="in recurrent or refractory primary or secondary central nervous system" exact="lymphoma" post="using thiotepa, busulfan and cyclophosphamide Leuk Lymphoma 56 2015"/>
  <result pre="K. Rubenstein J.L. New approaches in primary central nervous system" exact="lymphoma" post="Chin Clin Oncol 4 2015 11 25841718 32 Wiebe"/>
  <result pre="Acaba L. Treatment of patients with relapsed and resistant non-Hodgkin’s" exact="lymphoma" post="using total body irradiation, etoposide, and cyclophosphamide and autologous"/>
  <result pre="autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin" exact="lymphoma" post="with synchronous central nervous system involvement Clin Lymph Myeloma"/>
  <result pre="Clinical features, treatment, and survival of secondary central nervous system" exact="lymphoma" post="Blood 124 2014 5389 38 Maziarz R.T. Wang Z."/>
  <result pre="Wang Z. Zhang M.-J. Autologous haematopoietic cell transplantation for non-Hodgkin" exact="lymphoma" post="with secondary CNS involvement Br J Haematol 162 2013"/>
  <result pre="transplantation for patients with central nervous system involvement by non-Hodgkin’s" exact="lymphoma" post="Biol Blood Marrow Transplant 6 2000 352 358 10905773"/>
  <result pre="Goldstone A.H. Autologous bone marrow transplantation for patients with non-Hodgkin’s" exact="lymphoma" post="and CNS involvement: those transplanted with active CNS disease"/>
  <result pre="and outcome of elderly patients with primary central nervous system" exact="lymphoma" post="(PCNSL)—a systematic review and individual patient data meta-analysis Ann"/>
  <result pre="L.S. Panageas K.S. Delayed neurotoxicity in primary central nervous system" exact="lymphoma" post="Arch Neurol 62 2005 1595 1600 16216945 47 Ferreri"/>
  <result pre="high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary CNS" exact="lymphoma" post="(PCNSL): results of the second randomization of the IELSG32"/>
  <result pre="Dureau S. Radiotherapy or autologous stem-cell transplantation for primary CNS" exact="lymphoma" post="in patients 60 years of age and younger: results"/>
  <result pre="Introduction of novel agents in the treatment of primary CNS" exact="lymphoma" post="Neuro Oncol 21 2019 306 313 30423172 51 Mendez"/>
 </snippets>
</snippetsTree>
